Agios Pharma (AGIO) Appoints New CFO

August 16, 2016 7:32 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) announced that Andrew Hirsch is joining the company as chief financial officer, effective September 19, 2016. Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics.

"I am thrilled to welcome Andrew to the Agios team at this pivotal time as we advance programs across our IDH and PKR portfolios and get closer to making our first medicines available to patients," said David Schenkein, M.D., chief executive officer at Agios. "Andrew’s leadership experience and work across a wide range of areas of the business will be instrumental as we build for the future and work to achieve our vision of building a sustainable multi-product biopharmaceutical company.”

Prior to being named president and chief executive officer at BIND, Mr. Hirsch held several other leadership positions at the company, including chief operating officer and chief financial officer. Prior to joining BIND, he was chief financial officer at Avila Therapeutics until its acquisition by Celgene and held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including vice president of Corporate Strategy and M&A and program executive for the Tecfidera development team. He holds a Masters of Business Administration from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.

“I look forward to joining Agios at this exciting time and helping the team deliver on its vision for the future,” said Andrew Hirsch. “It’s rare to see the research and development productivity that Agios has delivered in such a short period of time and I am excited about the potential to advance those scientific breakthroughs to benefit patients.”

Glenn Goddard, senior vice president of finance, will be leaving the company at the end of September to pursue other opportunities. He will work closely with Andrew to ensure an orderly transition of finance activities.

"I want to sincerely thank Glenn for his many contributions as a key member of the Agios leadership team," said David Schenkein, M.D., chief executive officer at Agios. "Glenn has helped lead the company from an early phase research organization through our initial public offering to now building late-stage development and commercial capabilities. His work has been essential to positioning us for future success and growth across the business."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Management Changes, Management Comments

Related Entities

Definitive Agreement, IPO

Add Your Comment